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ABSTRACT
This preliminary study evaluated the use of the
Platelia Candida antigen kit for the diagnosis of
invasive candidosis in 70 of 184 pre-term infants
admitted to a neonatal intensive care unit
between March 2004 and March 2006. The fre-
quency of conﬁrmed candidaemia was 6.5%. The
sensitivity and speciﬁcity of the assay were 94.4%
and 94.2%, respectively, with a positive predic-
tive value of 85% and a negative predictive value
of 98%. These results suggest that the inclusion of
regular serological surveillance for mannanaemia
in some pre-term infants would complement
blood cultures for the early detection of candido-
sis.
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The incidence of candidaemia in neonatal inten-
sive care units (NICUs) is steadily increasing
[1–3]. Pre-term and low birth-weight infants are
particularly susceptible to infection because of
their immature immune system, disruptions in
their cutaneous barrier and iatrogenic factors
[4,5]. Clinical signs of invasive candidosis can be
non-speciﬁc, and diagnosis is still based mostly
on blood cultures; however, blood cultures are
thought to be positive for Candida in only 24–60%
of cases [6,7]. In view of this limitation, other
techniques to facilitate a diagnosis of invasive
fungal infection have been investigated. Mannan,
a high molecular weight polysaccharide found in
the cell wall of Candida spp., can be measured in
blood [8], but serological data concerning the
mannan antigen are very limited for patients in
NICUs. Accordingly, this report presents
preliminary data from an observational study
concerning the use of Platelia Candida antigen kits
(Bio-Rad, Segrate, Italy) for the diagnosis of
invasive candidosis in pre-term infants.
In the present analysis, the mannan antigen test
was considered positive when at least two serum
samples with mannan levels of ‡0.5 ng ⁄mL were
obtained. All other cases, i.e., only one positive
result or intermediate results, were considered to
be negative. All positive results were interpreted
in the context of the patient’s clinical, radiological
and laboratory data [9]. Proven candidosis,
deﬁned in the present study as clinical signs of
sepsis and positive blood culture, was observed in
12 of 184 patients admitted to the NICU between
March 2004 and March 2006, i.e., a frequency of
6.5%. Seventy patients were included in this
preliminary analysis, based on the availability of
at least three mannan antigen tests during their
stay in the NICU. The mean number of serum
samples ⁄patient was 3.9. The method used was as
described previously [10].
Of the 12 patients with proven candidosis, 11
were positive according to the mannan antigen
test and one was negative. The latter patient had
fungaemia caused by Candida parapsilosis. Of the
remaining 58 patients, 49 were negative accord-
ing to the mannan antigen test and blood
cultures, while nine were negative according to
fungal and bacterial blood cultures, but positive
according to the mannan antigen test. Three of
these patients were not considered to be suffer-
ing from invasive candidosis, because all coloni-
sation cultures were negative and antibacterial
therapy was effective in resolving the clinical
conditions. Therefore, the mannan test results for
these three patients should be considered to be
false-positives. The remaining six patients were
considered to be suffering from invasive
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candidosis. Indeed, alterations in the laboratory
parameters (quantitative C-reactive protein, leu-
kocytosis, neutrophilia), despite aggressive
broad-spectrum antibiotic therapy for at least
2 days, an elevated level of Candida intestinal
colonisation and, particularly, an improvement in
clinical symptoms following administration of
antifungal drugs, supported this hypothesis. Two
of these patients also had a previous positive
Candida culture from an intravascular catheter
tip. The characteristics of infants with proven or
presumed candidosis, or without candidosis, are
summarised in Table 1.
Based on these results, the sensitivity and
speciﬁcity of the Platelia Candida antigen test for
cases of proven and probable candidosis were
94.4% and 94.2%, respectively. The positive
predictive value and negative predictive value
were 85% and 98%, respectively. For the 12
cases of proven candidosis, sensitivity was
91.7%, speciﬁcity was 84.5%, the positive pre-
dictive value was 55%, and the negative predic-
tive value was 98%. For eight patients with
proven candidosis, the antigen test was positive
before blood culture sampling, for one patient on
the day of blood culturing, and for three patients
during the following days. Notably, for the
initial eight patients, the test was positive
between the fourth and 18th days before blood
cultures became positive (median value
8.5 days). For six patients with proven candido-
sis, it was possible to obtain serological data at
diagnosis and after 3 and 6 weeks (Fig. 1). These
patients were treated with liposomal amphoter-
icin B (1–5 mg ⁄ kg ⁄day) for a period of 6–7
weeks following their diagnosis.
In conclusion, this preliminary study suggests
that the inclusion of the mannan antigen deter-
mination test in a microbiological investigation of
at-risk patients in NICUs may be a useful contri-
bution to the diagnosis of invasive candidosis and
to effective therapy. The Platelia Candida assay
showed a greater sensitivity in NICU patients
than the global sensitivity of 51.5% reported by
Sendid et al. [10] for intensive care unit and
haematology patients with clinically suspected
systemic candidosis. The greater sensitivity
observed in the present study was probably
associated with an absence of circulating anti-
mannan antibodies, or a low concentration of
circulating lectins (mannose-binding protein), or
to the pathophysiology of candidosis in neonates.
Nevertheless, it is important to note the low
sensitivity for the detection of C. parapsilosis and
Candida krusei infection. This difference in the
sensitivity for antigenic detection of different
species is consistent with the nature of the Candida
mannose epitope recognised by the EBCA1
monoclonal antibody used in the test [10–12].
Nevertheless, since the frequency of C. parapsilosis
and C. krusei recovery in the NICU was £20% in
terms of blood culture and colonisation isolates,
the Platelia Candida assay could be a good test for
serological monitoring of patients with Candida
colonisation, who show the highest frequency of
invasive candidosis [13], and could allow the
possibility of early diagnosis, as observed in this
preliminary study, in c. 50% of patients with
invasive Candida infection.
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Fig. 1. Mean levels ± SE of mannan antigen observed in
six patients with proven candidosis at diagnosis and after
therapy with liposomal amphotericin B for 3 and 6 weeks.
Table 1. Characteristics and test results of infants with and without proven ⁄probable candidosis
n M ⁄ F
Gestational
age (weeks)a
Birth-weight
(g)a
Mechanical ventilation Parenteral nutrition Positive
blood
culture
Positive
antigen
testb<15 days >15 days <15 days >15 days
Proven and probable candidosis 18 8 ⁄ 10 30.72 ± 3.31 1622 ± 556 13 5 7 11 12 17
Without candidosis 52 25 ⁄ 27 34.9 ± 3.1 2262 ± 692 12 0 39 1 0 3
M, male; F, female.
aMean value ± SD.
bAt least two positive serum samples from the patient.
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ABSTRACT
The clinical importance of zygomycosis, an
emerging and frequently fatal mycotic disease,
has increased during recent years. This report
describes an identiﬁcation method based on PCR
ampliﬁcation and sequencing of the high-afﬁnity
iron permease 1 gene (FTR1). Primers and ampli-
ﬁcation protocols were established and tested for
the identiﬁcation of Rhizopus oryzae, Rhizopus
microsporus var. rhizopodiformis, R. microsporus
var. oligosporus, Rhizopus schipperae, Rhizopus
niveus and Rhizopus stolonifer. Rhizomucor and
Syncephalastrum could be identiﬁed at the genus
level. PCR–restriction fragment length polymor-
phism analysis of the ampliﬁed gene fragment
using AluI digestion distinguished three sub-
groups among the R. oryzae isolates.
Keywords Identiﬁcation, iron permease 1 gene,
Mucorales, PCR–restriction fragment length polymor-
phism analysis, Rhizopus, zygomycosis
Original Submission: 27 April 2007; Revised Sub-
mission: 20 October 2007; Accepted: 12 November
2007
Clin Microbiol Infect 2008; 14: 393–397
10.1111/j.1469-0691.2007.01932.x
Corresponding author and reprint requests: T. Papp, Depart-
ment of Microbiology, University of Szeged, Ko¨ze´p fasor 52,
Szeged H-6723, Hungary
E-mail: pappt@bio.u-szeged.hu
Research Notes 393
 2008 The Authors
Journal Compilation  2008 European Society of Clinical Microbiology and Infectious Diseases, CMI, 14, 377–397
